QuidelOrtho Appoints Two Executives to Drive Quality and Innovation Globally
PorAinvest
lunes, 7 de julio de 2025, 7:02 am ET1 min de lectura
JNJ--
Devon Burek, who brings over 20 years of experience from Roche, will lead QuidelOrtho's global quality organization. Her primary focus will be on creating a streamlined, global approach to elevate product quality and enhance operational effectiveness. Prior to joining QuidelOrtho, Burek held various quality leadership roles across diagnostics and R&D at Roche.
Sergio Gadaleta, who holds a PhD in chemistry, will oversee QuidelOrtho's global clinical trial strategy and regulatory submissions. His extensive experience spans senior roles at BD, 3M, Johnson & Johnson, and the FDA. Gadaleta's strategic mindset and scientific rigor will be instrumental in guiding the company's innovations through clinical and regulatory pathways.
These appointments reflect QuidelOrtho's dedication to building a high-performance organization rooted in scientific excellence, customer trust, and global scale. The company continues to drive productivity and efficiency within its R&D team, with these additions further emphasizing its commitment to innovation and regulatory compliance.
For more information, visit quidelortho.com.
References:
[1] https://www.stocktitan.net/news/QDEL/quidel-ortho-strengthens-leadership-team-with-appointments-of-senior-sfkyzd1hmbua.html
[2] https://www.prnewswire.com/news-releases/quidelortho-strengthens-leadership-team-with-appointments-of-senior-vice-presidents-for-global-quality-and-clinical--regulatory-affairs-302498733.html
MMM--
QDEL--
QuidelOrtho Corporation has appointed Devon Burek as SVP of Global Quality and Sergio Gadaleta as SVP of Clinical and Regulatory Affairs. The appointments reflect the Company's investment in operational excellence, product quality, and regulatory innovation to support global growth. Burek will lead the quality organization, while Gadaleta will oversee clinical and regulatory affairs.
QuidelOrtho Corporation (NASDAQ: QDEL) has recently bolstered its leadership team with the appointments of Devon Burek as Senior Vice President of Global Quality and Sergio Gadaleta as Senior Vice President of Clinical and Regulatory Affairs. These strategic hires underscore the company's commitment to operational excellence, product quality, and regulatory innovation to support its global growth.Devon Burek, who brings over 20 years of experience from Roche, will lead QuidelOrtho's global quality organization. Her primary focus will be on creating a streamlined, global approach to elevate product quality and enhance operational effectiveness. Prior to joining QuidelOrtho, Burek held various quality leadership roles across diagnostics and R&D at Roche.
Sergio Gadaleta, who holds a PhD in chemistry, will oversee QuidelOrtho's global clinical trial strategy and regulatory submissions. His extensive experience spans senior roles at BD, 3M, Johnson & Johnson, and the FDA. Gadaleta's strategic mindset and scientific rigor will be instrumental in guiding the company's innovations through clinical and regulatory pathways.
These appointments reflect QuidelOrtho's dedication to building a high-performance organization rooted in scientific excellence, customer trust, and global scale. The company continues to drive productivity and efficiency within its R&D team, with these additions further emphasizing its commitment to innovation and regulatory compliance.
For more information, visit quidelortho.com.
References:
[1] https://www.stocktitan.net/news/QDEL/quidel-ortho-strengthens-leadership-team-with-appointments-of-senior-sfkyzd1hmbua.html
[2] https://www.prnewswire.com/news-releases/quidelortho-strengthens-leadership-team-with-appointments-of-senior-vice-presidents-for-global-quality-and-clinical--regulatory-affairs-302498733.html
Divulgación editorial y transparencia de la IA: Ainvest News utiliza tecnología avanzada de Modelos de Lenguaje Largo (LLM) para sintetizar y analizar datos de mercado en tiempo real. Para garantizar los más altos estándares de integridad, cada artículo se somete a un riguroso proceso de verificación con participación humana.
Mientras la IA asiste en el procesamiento de datos y la redacción inicial, un miembro editorial profesional de Ainvest revisa, verifica y aprueba de forma independiente todo el contenido para garantizar su precisión y cumplimiento con los estándares editoriales de Ainvest Fintech Inc. Esta supervisión humana está diseñada para mitigar las alucinaciones de la IA y garantizar el contexto financiero.
Advertencia sobre inversiones: Este contenido se proporciona únicamente con fines informativos y no constituye asesoramiento profesional de inversión, legal o financiero. Los mercados conllevan riesgos inherentes. Se recomienda a los usuarios que realicen una investigación independiente o consulten a un asesor financiero certificado antes de tomar cualquier decisión. Ainvest Fintech Inc. se exime de toda responsabilidad por las acciones tomadas con base en esta información. ¿Encontró un error? Reportar un problema

Comentarios
Aún no hay comentarios